Helsinn Group, of Lugano, Switzerland, said the European Medicines Agency determined that the marketing authorization application was valid for netupitant-palonosetron fixed-dose combination for cancer. Read More
Galapagos NV, of Mechelen, Belgium, said the first clinical centers have been opened for enrollment in the Phase II study in Crohn’s disease with GLPG0634, a selective JAK1 inhibitor. Read More
Kiadis Pharma BV, of Amsterdam, the Netherlands, said it initiated a collaboration to identify and characterize leukemia-specific T cells in Kiadis’ lead product, ATIR, that would be responsible for the graft-vs.-leukemia effect of the T-cell immunotherapy product. Read More
Patrys Ltd., of Melbourne, Australia, said it has raised a further $925,000 before costs through the placement of 18.5 million shares at $0.05 per share as part of a shortfall from their recent rights Issue. Read More
Biopharma stalwart Amgen Inc. maintained its slow-but-steady growth for the fourth quarter and full year 2013, beating consensus estimates and offering conservative guidance for 2014 as investors await key pipeline milestones, including the possible new drug application filing for evolocumab, its anti-PCSK9 drug in a tight race with Sanofi SA and Regeneron Pharmaceuticals Inc. in the blockbuster cardiovascular space. Read More
Metastatic, castration-resistant prostate cancer as a therapeutic space is heating up still more with the disclosure by Medivation Inc. and partner Astellas Pharma Inc. of powerful data with Xtandi (enzalutamide) from the Phase III study known as PREVAIL. Read More
In a year that was driven largely by significant growth in its expanded multiple sclerosis (MS) franchise, Cambridge, Mass.-based Biogen Idec Inc. reported $6.9 billion in revenue, a 26 percent increase compared to 2012, in its full year and fourth quarter 2013 financial results just released. Read More
It is an article of faith among many health-conscious individuals that antioxidants are good for you – an article of faith that leads to a lot of vitamin sales. And in the typical “more is better” rationale that fuels many of those sales in the first place, most supplements provide many times the U.S. recommended daily allowance (RDA). Read More
